New bedro-oils are made by extracting oils from Bedrocan Canada's line of standardized whole-flower cannabis varieties using CO2 supercritical extraction equipment. Once the crude extraction is purified, it is balanced with organic sunflower oil to create a versatile product that can be consumed on its own or used for baking or cooking.

"Many of our clients have expressed a desire to ingest cannabis oils to either compliment or substitute the inhaled route," said Marc Wayne, President, Bedrocan Canada. "We're proud to offer this new option for patients who, whether for convenience or for health reasons, prefer to ingest their medical cannabis."

Along with Bedrocan Canada's sister company, Tweed Inc., the company has committed $50,000 toward partnerships with leading organizations committed to responsible use education. $1 from every bottle of 10:1 bedro-oils sold will also go towards important initiatives such as a recently announced partnership with MADD Canada and the Canadian Drug Policy Coalition.

Keeping with Bedrocan Canada's commitment to True Compassionate Pricing, bedro-oils will be sold for $110 per 100ml bottle.

About Bedrocan CanadaBedrocan Canada is focused on medicinal cannabis production and research, including, the EQUAL Study, which is currently enrolling patients and evaluating how cannabis is affecting their quality of life of Canadian patients. Bedrocan's standardized strains have been used by thousands of patients in seven countries around the world. www.bedrocan.ca

About Canopy Growth CorporationCanopy Growth is Canada's first publicly traded medical marijuana company and the first geographically diversified producer with multiple licenses under the Marihuana for Medical Purposes Regulations. Through its wholly owned subsidiaries, Tweed, Tweed Farms, and Bedrocan Canada, the Company operates three state-of-the-art production facilities in Ontario and distributes marijuana across the country to Canadian patients managing a host of medical conditions. The Company is dedicated to educating healthcare practitioners, providing consistent access to high quality medication, conducting robust clinical research, and furthering the public's understanding of how marijuana is used for medical purposes. www.canopygrowth.com

Forward Looking StatementThis news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or any of its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.Although Canopy Growth Corp. has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The factors identified above are not intended to represent a complete list of the factors that could affect the Company or any of its subsidiaries. The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corp. does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.